Patents by Inventor Sanxing Sun
Sanxing Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116975Abstract: The present application relates to novel compounds that have modulating or activating effect on the activity of adenosine A3 receptor, preparation methods for the series of compounds, pharmaceutical compositions of the series of compounds, and pharmaceutical uses of the series of compounds.Type: ApplicationFiled: December 29, 2021Publication date: April 11, 2024Inventors: Chongbo HU, Jinqi YE, Shuhua PAN, Ning Hu, Tingting PAN, Long ZHAO, Zhengshu CHEN, Sanxing SUN
-
Patent number: 11858942Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.Type: GrantFiled: June 26, 2018Date of Patent: January 2, 2024Assignee: ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.Inventors: Sanxing Sun, Jinqi Ye, Long Zhao, Chongbo Hu, Zhengshu Chen
-
Patent number: 11845751Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.Type: GrantFiled: June 26, 2018Date of Patent: December 19, 2023Assignee: ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.Inventors: Sanxing Sun, Long Zhao, Chongbo Hu, Zhengshu Chen, Jinqi Ye
-
Publication number: 20230048888Abstract: The present application relates to use of a triazolotriazine derivative or a pharmaceutically acceptable solvate or salt thereof in the preparation of a drug for treating diseases, and a method for treating diseases.Type: ApplicationFiled: December 25, 2020Publication date: February 16, 2023Applicant: ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.Inventors: Sanxing SUN, Zhengshu CHEN, Jinqi YE, Long ZHAO, Chongbo HU, Yong YANG, Feng GUAN, Shuhua PAN, Ning HU, Tingting PAN, Guowei SONG, Fangjie HOU
-
Publication number: 20210332055Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.Type: ApplicationFiled: June 26, 2018Publication date: October 28, 2021Inventors: Sanxing SUN, Long ZHAO, Chongbo HU, Zhengshu CHEN, Jinqi YE
-
Publication number: 20210292334Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.Type: ApplicationFiled: June 26, 2018Publication date: September 23, 2021Inventors: Sanxing SUN, Jinqi YE, Long ZHAO, Chongbo HU, Zhengshu CHEN
-
Patent number: 10646585Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.Type: GrantFiled: December 19, 2018Date of Patent: May 12, 2020Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventors: Sanxing Sun, Robert Yongxin Zhao, Xing Li, Huihui Guo, Junxiang Jia, Hongsheng Xie, Xiaomai Zhou, Yuanyuan Huang, Qingliang Yang, Xiaotao Zhuo, Hangbo Ye, Shun Gai, Lan Qu, Wenjun Li, Chen Lin
-
Patent number: 10456479Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.Type: GrantFiled: March 19, 2015Date of Patent: October 29, 2019Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventors: Sanxing Sun, Robert Yongxin Zhao, Xing Li, Huihui Guo, Junxiang Jia, Hongsheng Xie, Xiaomai Zhou, Yuanyuan Huang, Qingliang Yang, Xiaotao Zhuo, Hangbo Ye, Shun Gai, Lan Qu, Wenjun Li, Chen Lin
-
Publication number: 20190125894Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.Type: ApplicationFiled: December 19, 2018Publication date: May 2, 2019Applicant: HANGZHOU DAC BIOTECH CO., LTD.Inventors: Sanxing SUN, Robert Yongxin ZHAO, Xing LI, Huihui GUO, Junxiang JIA, Hongsheng XIE, Xiaomai ZHOU, Yuanyuan HUANG, Qingliang YANG, Xiaotao ZHUO, Hangbo YE, Shun GAI, Lan QU, Wenjun LI, Chen LIN
-
Publication number: 20180110876Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.Type: ApplicationFiled: March 19, 2015Publication date: April 26, 2018Applicant: HANGZHOU DAC BIOTECH CO., LTD.Inventors: Sanxing SUN, Robert Yongxin ZHAO, Xing LI, Huihui GUO, Junxiang JIA, Hongsheng XIE, Xiaomai ZHOU, Yuanyuan HUANG, Qingliang YANG, Xiaotao ZHUO, Hangbo YE, Shun GAI, Lan QU, Wenjun LI, Chen LIN
-
Patent number: 8258301Abstract: Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of Urotensin II with its receptor, including cardiovascular diseases. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds, and intermediates useful in these processes.Type: GrantFiled: May 12, 2008Date of Patent: September 4, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Anne Bettina Eldrup, Ingo Andreas Mugge, Fariba Soleymanzadeh, Sanxing Sun, Yunlong Zhang
-
Publication number: 20100121051Abstract: Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of Urotensin II with its receptor, including cardiovascular diseases. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds, and intermediates useful in these processes.Type: ApplicationFiled: May 12, 2008Publication date: May 13, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Anne Bettina Eldrup, Ingo Andreas Mugge, Fariba Soleymanzadeh, Sanxing Sun, Yunlong Zhang
-
Patent number: 7465745Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.Type: GrantFiled: May 31, 2005Date of Patent: December 16, 2008Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Eugene R. Hickey, Wiemen Liu, Sanxing Sun, Yancey David Ward, Erick Richard Roush Young
-
Patent number: 7405225Abstract: Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.Type: GrantFiled: August 18, 2005Date of Patent: July 29, 2008Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Charles L. Cywin, Zhidong Chen, Jonathan Emeigh, Roman Wolfgang Fleck, Ming-Hong Hao, Eugene Hickey, Weimin Liu, Daniel Richard Marshall, Tina Morwick, Peter Nemoto, Ronald John Sorcek, Sanxing Sun, Jiang-Ping Wu
-
Patent number: 7329764Abstract: Disclosed are compounds of the formula I shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents.Type: GrantFiled: July 29, 2004Date of Patent: February 12, 2008Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Zhidong Chen, John David Ginn, Eugene Richard Hickey, Weimin Liu, Can Mao, Tina Marie Morwick, Peter Allen Nemoto, Denice Spero, Sanxing Sun
-
Patent number: 7326719Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases.Type: GrantFiled: March 1, 2004Date of Patent: February 5, 2008Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Eugene R. Hickey, Weimin Liu, Sanxing Sun, Yancey David Ward, Erick Richard Roush Young
-
Patent number: 7312211Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases.Type: GrantFiled: August 26, 2004Date of Patent: December 25, 2007Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
-
Patent number: 7279472Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases.Type: GrantFiled: September 9, 2004Date of Patent: October 9, 2007Assignee: Boehringer Ingelheim Pharmaceuticals Inc.Inventors: Michel Jose Emmanuel, Leah L. Frye, Eugene R. Hickey, Weimin Liu, Tina Marie Morwick, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
-
Patent number: 7241758Abstract: Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.Type: GrantFiled: October 15, 2002Date of Patent: July 10, 2007Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Ming-Hong Hao, Sanxing Sun
-
Patent number: 7056915Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases.Type: GrantFiled: April 24, 2003Date of Patent: June 6, 2006Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young